Penpulimab 派安普利单抗|cas:2350298-92-7|西域试剂

Penpulimab 派安普利单抗,98.80%

产品编号：Bellancom-P99108| CAS NO：2350298-92-7

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P99108	￥1100.00	杭州北京（现货）
Bellancom-P99108	￥2700.00	杭州北京（现货）
Bellancom-P99108	￥4200.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Penpulimab 派安普利单抗

产品介绍

Penpulimab 是一种 IgG1 抗 PD-1 单克隆抗体，具有抗肿瘤活性。

生物活性

Penpulimab is an IgG1 backbone anti-PD-1 monoclonal antibody with antitumor activities.

体外研究

Penpulimab demonstrates better stability and a lower level of host-cell protein residue compared with IgG4 backbone anti-PD-1 antibodies.
Penpulimab does not mediate complement-dependent cytotoxicity (CDC) or antibody-dependent cell-mediated cytotoxicity (ADCC) and induces no remarkable IL-6 and IL-8 release by activated macrophages.
Penpulimab exhibits slower binding off-rate for human PD-1 than Nivolumab (HY-P9903) and Pembrolizumab (HY-P9902).
Penpulimab potentiates T cell activation via PD-1/PD-L1 blockade.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Penpulimab (5 mg/kg; i.p.; twice a week, 3weeks) inhibits tumor growth in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	MC38-hPD-L1 tumor-bearing B-hPD-1 humanized mouse model
Dosage:	5 mg/kg
Administration:	IP, twice a week, 3weeks
Result:	Showed moderate inhibition of tumor growth (tumor volume: 58.4% of control group). Treatment combined with anlotinib (1 mg/kg, every day, p.o) significantly decreased tumor volume to 36.5% of control group.

体内研究

Penpulimab (5 mg/kg; i.p.; twice a week, 3weeks) inhibits tumor growth in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	MC38-hPD-L1 tumor-bearing B-hPD-1 humanized mouse model
Dosage:	5 mg/kg
Administration:	IP, twice a week, 3weeks
Result:	Showed moderate inhibition of tumor growth (tumor volume: 58.4% of control group). Treatment combined with anlotinib (1 mg/kg, every day, p.o) significantly decreased tumor volume to 36.5% of control group.